Olympus, a leading global medical technology company, made its first U.S. demonstration of the OLYSENSE™ Platform with the CADDIE™ computer-aided detection device at the Digestive Disease Week (DDW) annual meeting, held from May 4-6, 2023, in San Diego. The platform leverages cloud-based artificial intelligence (AI) to assist gastroenterologists in detecting suspected polyps during colonoscopies, enhancing clinical decision-making. Miquel Àngel Garcìa, Senior Vice President and General Manager for Endoscopy Ecosystem Solutions at Olympus Corporation, expressed enthusiasm about launching their AI solution in the U.S. market. He emphasized Olympus's commitment to providing cutting-edge endoscopy solutions that improve patient outcomes and support gastroenterologists throughout the entire care pathway. During DDW, Olympus showcased a comprehensive portfolio of solutions, including the OLYSENSE Platform, the CADDIE device, and other advanced technologies like the ENDOCUFF Vision™ device and Texture and Color Enhancement Imaging (TXI™). The CADDIE device specifically aims to increase the adenoma detection rate (ADR) by highlighting potential polyps using real-time AI analysis. This technology can help gastroenterologists identify more subtle and hard-to-spot abnormalities, potentially reducing the risk of missed diagnoses. The OLYSENSE Platform integrates seamlessly with Olympus's existing endoscopy systems, ensuring that healthcare providers can easily incorporate the new AI capabilities into their current workflows. Additionally, Olympus highlighted its range of hemostasis products, ERCP portfolio items, and the newly launched EU-ME3 ultrasound processor. The hemostasis products are designed to control bleeding during endoscopic procedures, while the ERCP portfolio supports advanced therapeutic interventions, such as bile duct stone removal and pancreatic disease management. The EU-ME3 ultrasound processor enhances diagnostic accuracy by providing high-quality images and minimizing potential risks associated with prolonged ultrasonic exposure. To complement these technological advancements, Olympus organized several educational sessions and physician talks at their booth (#5129). Collaborating with the American Society for Gastrointestinal Endoscopy (ASGE), these sessions aimed to educate physicians on the latest techniques and tools to improve ADR and manage bleeding effectively. Dr. Dennis Yang from Advent Health Medical Group led a presentation on the utility of image-enhanced endoscopy during endoscopic resection, providing valuable insights and practical guidance. Olympus’s presence at DDW underscores its ongoing commitment to innovation in the field of gastrointestinal (GI) care. By integrating AI and cloud connectivity, the company seeks to elevate the standards of endoscopic procedures, making them more accurate and efficient. However, it's important to note that technologies like TXI and RDI are supplementary tools and not meant to replace traditional histopathological sampling for definitive diagnosis. Safety precautions for the EU-ME3 ultrasound processor emphasize the need for proper use and care to avoid adverse effects on patients. Olympus Corporation of the Americas, a subsidiary of Olympus Corporation based in Tokyo, Japan, has been a pioneer in medical technology for over a century. Their focus on delivering optimal outcomes through innovative solutions highlights their dedication to improving the quality of healthcare worldwide. The company's extensive portfolio of GI care products, from advanced imaging technologies to therapeutic devices, demonstrates their comprehensive approach to supporting medical professionals. Industry insiders have praised Olympus's introduction of the OLYSENSE Platform and the CADDIE device, noting that they represent significant advancements in endoscopic polyp detection. The integration of AI and cloud computing is expected to not only enhance diagnostic accuracy but also streamline the overall process, potentially reducing the time needed for each procedure and improving patient comfort. Physicians and healthcare providers are eagerly awaiting further clinical trials and real-world applications to validate the technology's effectiveness and safety.